Comment on 'Dupilumab significantly improves sleep in adults with atopic dermatitis: results from the 12-week placebo-controlled period of the 24-week phase IV randomized double-blinded placebo-controlled DUPISTAD study'

In this letter to the editor, we respond to the article by Merola et al. titled 'Dupilumab significantly improves sleep in adults with atopic dermatitis: results from the 12-week placebo-controlled period of the 24-week phase IV randomized double-blinded placebo-controlled DUPISTAD study'. We add to the authors' discussion on the discrepancy between objective and subjective measures of sleep in people with atopic dermatitis treated with dupilumab.